# Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia

> **NCT02776605** · PHASE2 · UNKNOWN · sponsor: **PETHEMA Foundation** · enrollment: 30 (actual)

## Conditions studied

- ALL

## Interventions

- **DRUG:** Prednisone
- **DRUG:** Vincristine
- **DRUG:** Daunorubicin
- **DRUG:** Prednisone
- **DRUG:** Ponatinib
- **DRUG:** Mercaptopurine
- **DRUG:** Methotrexate
- **DRUG:** VP-16
- **DRUG:** ARA-C:
- **DRUG:** TIT
- **DRUG:** Ponatinib
- **PROCEDURE:** Autologous transplantation
- **PROCEDURE:** Allo transplantation

## Key facts

- **NCT ID:** NCT02776605
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06
- **Primary completion:** 2020-08-05
- **Final completion:** 2023-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2022-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02776605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02776605, "Ponatinib With Chemotherapy for Young Adults Ph Positive Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02776605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*